- Home
- LAZR vs MNPR Comparison
LAZR vs MNPR Comparison
Compare LAZR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZR
- MNPR
- Stock Information
- Founded
- LAZR 2012
- MNPR 2014
- Country
- LAZR United States
- MNPR United States
- Employees
- LAZR N/A
- MNPR N/A
- Industry
- LAZR Auto Parts:O.E.M.
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- LAZR Consumer Discretionary
- MNPR Health Care
- Exchange
- LAZR Nasdaq
- MNPR Nasdaq
- Market Cap
- LAZR 246.4M
- MNPR 250.0M
- IPO Year
- LAZR N/A
- MNPR 2019
- Fundamental
- Price
- LAZR $6.16
- MNPR $40.25
- Analyst Decision
- LAZR Hold
- MNPR Strong Buy
- Analyst Count
- LAZR 8
- MNPR 4
- Target Price
- LAZR $42.56
- MNPR $43.00
- AVG Volume (30 Days)
- LAZR 1.8M
- MNPR 71.2K
- Earning Date
- LAZR 03-20-2025
- MNPR 03-27-2025
- Dividend Yield
- LAZR N/A
- MNPR N/A
- EPS Growth
- LAZR N/A
- MNPR N/A
- EPS
- LAZR N/A
- MNPR N/A
- Revenue
- LAZR $75,025,000.00
- MNPR N/A
- Revenue This Year
- LAZR $2.79
- MNPR N/A
- Revenue Next Year
- LAZR $68.80
- MNPR N/A
- P/E Ratio
- LAZR N/A
- MNPR N/A
- Revenue Growth
- LAZR 27.61
- MNPR N/A
- 52 Week Low
- LAZR $4.93
- MNPR $1.72
- 52 Week High
- LAZR $38.25
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- LAZR 48.64
- MNPR 49.34
- Support Level
- LAZR $5.30
- MNPR $38.80
- Resistance Level
- LAZR $7.43
- MNPR $45.60
- Average True Range (ATR)
- LAZR 0.62
- MNPR 5.19
- MACD
- LAZR 0.18
- MNPR -1.50
- Stochastic Oscillator
- LAZR 42.05
- MNPR 9.37
About LAZR Luminar Technologies Inc.
Luminar Technologies Inc is an automotive technology company ushering in a new era of vehicle safety and autonomy. It operates its business through the following segments: Autonomy Solutions and advanced Technologies and Services. The majority of revenue is earned from the Autonomy Solutions segment which engaged in the design, manufacturing, and sale of LiDAR sensors catering mainly to the OEMs in the automobile, commercial vehicle, robo-taxi, and adjacent industries and advanced Technologies and Services provides semiconductors and related components, as well as design, test and consulting services to the Autonomy Solutions segment and various third-party customers, including government agencies and defense contractors, in markets generally unrelated to autonomous vehicles.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.